What is the history of Arterial Tortuosity Syndrome?

Arterial Tortuosity Syndrome is a rare connective tissue disorder first described in the 1960s, characterized by the elongation and twisting of medium- and large-sized arteries. Our understanding of Arterial Tortuosity Syndrome has shifted from a purely clinical observation of vascular findings to a precise molecular diagnosis linked to mutations in the SLC2A10 gene.

When was Arterial Tortuosity Syndrome first identified?

The condition was first formally documented in medical literature in 1965 by Dr. M.M. Beighton, who recognized the distinct pattern of elongated, tortuous arteries in affected patients. For decades, the condition was often confused with other connective tissue disorders, such as Marfan syndrome or Loeys-Dietz syndrome, due to overlapping phenotypic features like joint hypermobility and craniofacial anomalies. It was not until the early 2000s that the specific genetic etiology of Arterial Tortuosity Syndrome was fully elucidated.

How has our understanding of Arterial Tortuosity Syndrome evolved?

The discovery of the SLC2A10 gene mutation in 2006 marked a revolutionary milestone in the study of Arterial Tortuosity Syndrome. This gene encodes the glucose transporter GLUT10. Research has since confirmed that Arterial Tortuosity Syndrome follows an autosomal recessive inheritance pattern, meaning both parents must carry a copy of the mutated gene for a child to be affected. This genetic breakthrough allowed for definitive prenatal and diagnostic testing, moving the field away from reliance on clinical observation alone.

What are the major milestones in managing this condition?

While there is no cure, the management of Arterial Tortuosity Syndrome has improved significantly through multidisciplinary care. Key milestones include:

• Increased use of non-invasive cardiovascular imaging (MRA and CTA) for routine monitoring.


• The implementation of prophylactic blood pressure management to reduce vascular stress.


• Improved surgical techniques for managing arterial stenoses and aneurysms.


• The growth of global patient registries, including the 7 members sharing experiences on DiseaseMaps.org, which help researchers track long-term outcomes.

Next steps

• Consult a cardiologist or vascular specialist experienced in connective tissue disorders.


• Request genetic counseling to understand the inheritance pattern of Arterial Tortuosity Syndrome.


• Connect with the Arterial Tortuosity Syndrome community on DiseaseMaps.org to share resources and support.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Arterial Tortuosity Syndrome.


• Orphanet: Rare disease database entry for Arterial Tortuosity Syndrome.


• OMIM (Online Mendelian Inheritance in Man): Entry #208050 regarding SLC2A10 mutations.


• PubMed: Original clinical studies regarding the identification of the SLC2A10 gene in patients with Arterial Tortuosity Syndrome.